Drug · Small Molecule

Imatinib

CI-DRUG-00000295Explore in graph →NCIt C62035 CHEMBL941 CIViC Approved

Regulatory

Approvals (67)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as IMATINIB (DIN 02521210) under ATC L01EA01 IMATINIB. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Apr 29, 2024	health-canada-dpd
CA

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	34	20	38	160	67	CA, EU, US	Nov 7, 2001	Aug 9, 1999
Leukemia	Approved	Phase 4	10	4	26	83	6	US	Apr 18, 2003	Aug 9, 1999
Non-Hodgkin Lymphoma	Phase3	Phase 3	0	0	1	2	0	—	—	2016-08
Malignant Breast Neoplasm	Phase2	Phase 2	1	1	0	3	0	—

Curated evidence

Clinical evidence (279)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–50 of 279 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 T315I + ABL1 Fusion1
Dasatinib + Imatinib

Clinical trials

Trials with this intervention (174)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 174 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06090669	Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency	recruiting	Phase 1	75	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT06124157	A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Molecule

Record

Kind: Small Molecule
Mechanism: Tyrosine-protein kinase ABL inhibitor; Platelet-derived growth factor receptor beta inhibitor; Stem cell growth factor receptor inhibitor; Bcr/Abl fusion protein inhibitor
Targets: 4 genes
UNII: 8A1O1M485B
Aliases: 4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, ACH-IMATINIB, APO-IMATINIB, CGP057148B, CGP-57148B, Glamox, GLEEVEC, GLEEVEC,STI-571, Glivec, GLIVEC, Imatinib, Imatinib Accord, Imatinib Actavis, Imatinib Koanaa, Imatinib medac, Imatinib Mesylate, IMATINIB MESYLATE, IMATINIB MESYLATE 400 MG, IMATINIB MESYLATEGLEEVECGLIVECIMATINIBSTI571CGP 571484-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]-PHENYL]BENZAMIDE, IMATINIB (STI571), Imatinib Teva, Imatinib Teva B.V., IMKELDI, JAMP IMATINIB, MINT-IMATINIB, MYLAN-IMATINIB, NAT-IMATINIB, NSC-743414, NSC-759854, PMS-IMATINIB … (+7)

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (63)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01EA01	IMATINIB

CSF1R Fusion2
GW-2580 + ImatinibSubstitutes	Acute Lymphoblastic Leukemia	Predictive	D	Supports Sensitivity Response	3	accepted	EID403 Cell lines with MEF2D-CSF1R fusion show sensitivity to the tyrosine kinase inhibitors Imatinib and GW-2580. PMID 24186003 · Lilljebjörn et al., 2014 · Open in CIViC	civic
Imatinib	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	C	Supports Sensitivity Response	3	accepted	EID9360 This study describes a cohort of 24 patients with BCR-ABL1-like B-ALL and ABL-class kinase rearrangement exposed to TKI frontline or at relapse, who showed favorable MRD response and outcome. Specific… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC	civic

ABL1 Fusion4
Imatinib	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	accepted	EID259 Treatment of Philadelphia chromosome positive leukemias with imatinib results in high rates of complete remission in patients with CML. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC	civic
〃	Acute Myeloid LeukemiaCURATED_BROADER	Predictive	D	Supports Resistance	3	accepted	EID232 BCR-ABL fusions have been found to contribute to imatinib resistance in AML cell lines. PMID 12476305 · Nimmanapalli et al., 2002 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID260 The clinical use of imatinib in patients with BCR-ABL fusion has resulted in drastic prognostic improvements in patients with CML. PMID 20537386 · An et al., 2010 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	A	Supports Sensitivity Response	5	accepted	EID344 BCR-ABL inhibitors such as imatinib have lead to significantly improved prognosis, response rate, overall survival, and patient outcome in CML patients compared to previous therapeutic regimens. PMID 20537386 · An et al., 2010 · Open in CIViC	civic

PDGFRA Fusion2
Imatinib	B Acute Lymphoblastic LeukemiaALIAS	Predictive	C	Supports Sensitivity Response	3	accepted	EID7990 A 47-year-old man was diagnosed with pre-B-cell acute lymphoblastic leukemia. FISH and nested PCR revealed the patient had a t(4;22)(q12;11) translocation that created an in-frame BCR-PDGFRA fusion. T… (full text at CIViC) PMID 12944919 · Trempat et al., 2003 · Open in CIViC	civic
Chemotherapy + ImatinibCombination	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	C	Supports Sensitivity Response	2	submitted	EID12582 A 39-year-old Chinese man was hospitalized in May 2021 with concerns of thirst and weight loss. Immature B lymphocytes were detected in blood (83.8%) and bone marrow (87%) and FISH showed the absence … (full text at CIViC) PMID 41143846 · Hua et al., 2024 · Open in CIViC	civic

PDGFRA Fusion2
Chemotherapy + ImatinibCombination	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	submitted	EID12566 A previously healthy 2-year-old girl presented with right supraorbital swelling, hepatosplenomegaly, anemia (Hb 8.2 g/dl) and leukocytosis (WBC 19.5 × 109/L) with eosinophilia of 32% and an absolute e… (full text at CIViC) PMID 36589160 · Akiely et al., 2022 · Open in CIViC	civic
〃	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	C	Supports Sensitivity Response	2	submitted	EID12565 A 10‐year‐old female patient presented with pancytopenia and normal eosinophils and had the diagnosis of B‐lymphoblastic leukemia/lymphoma. FISH identified a CHIC2 deletion, suggestive of FIP1L1::PDG… (full text at CIViC) PMID 39996417 · Nunn et al., 2025 · Open in CIViC	civic

ABL1 Fusion3
Dasatinib + ImatinibSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID12385 Functional activity and treatment response were evaluated for several fusions identified in patients with gene expression profiles showing BCR::ABL1-like B-ALL. Phosphoflow on leukemic samples from 2 … (full text at CIViC) PMID 22897847 · Roberts et al., 2012 · Open in CIViC	civic
Dasatinib + Imatinib + Nilotinib + PonatinibSubstitutes	B Lymphoblastic Leukemia/LymphomaCURATED_BROADER	Predictive	D	Does Not Support Sensitivity Response	2	accepted	EID9150 A 22-year-old male with B-cell acute lymphoblastic leukemia was treated with induction therapy. FISH using a BCR-ABL1 probe demonstrated 50-80 extrachromosomal copies of ABL1; FISH using probes to the… (full text at CIViC) PMID 23175662 · Eyre et al., 2012 · Open in CIViC	civic
Dasatinib + ImatinibCombination	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	Predictive	B	Supports Sensitivity Response	3	submitted	EID13330 In a cohort of six patients with NUP214::ABL1-positive Ph-like B-ALL, detected by multiplex molecular assays for fusion transcript identification, including RNA sequencing, treatment with ABL-directed… (full text at CIViC) PMID 31434701 · Tanasi et al., 2019 · Open in CIViC	civic